Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Effects of fish oil containing eicosapentaenoic acid and docosahexaenoic acid on dystrophic mdx mice

Texto completo
Autor(es):
Mauricio, Adriana Fogagnolo [1] ; Minatel, Elaine [1] ; Santo Neto, Humberto [1] ; Marques, Maria Julia [1]
Número total de Autores: 4
Afiliação do(s) autor(es):
[1] Univ Estadual Campinas UNICAMP, Dept Biol Estrut & Func, Inst Biol, BR-13083970 Campinas, SP - Brazil
Número total de Afiliações: 1
Tipo de documento: Artigo Científico
Fonte: Clinical Nutrition; v. 32, n. 4, p. 636-642, AUG 2013.
Citações Web of Science: 18
Resumo

Background Ea aims: In Duchenne muscular dystrophy (DMD) and in the mdx mouse model of DMD, the lack of dystrophin leads to muscle degeneration and inflammation contributes to progression of the disease. In this study, we evaluated the effects of commercially available fish oil containing EPA and docosahexaenoic acid (DHA) on mdx. Methods: Mdx mice (14 days old) were treated with fish oil (FDC Vitamins; 0.002 g EPA and 0.001 g DHA) for 16 days by gavage. Control mdx mice received mineral oil (Nujol). Grip strength measurement was used for functional evaluation. The stemomastoid, diaphragm and biceps brachii muscles were removed and processed for histopathology and Western blot analysis. Results: Fish oil decreased creatine kinase and myonecrosis. In all muscles studied, the inflammatory area was significantly reduced after treatment (18.0 +/- 3.0% inflammatory area in untreated mdx mice versus 4.0 +/- 1% in treated mdx mice). Fish oil protected against the loss of muscle strength. Fish oil significantly reduced the levels of TNF-alpha and the levels of 4-HNE-protein adducts (30-34% reduction for both) in all muscles studied. Conclusions: Commercially available fish oil may be potentially useful to ameliorate dystrophic progression of skeletal muscles, deserving further clinical trials in DMD patients. (C) 2012 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved. (AU)

Processo FAPESP: 11/02474-4 - Tratamento in vivo e in vitro com bloqueador de cálcio e antioxidante em camundongos mdx
Beneficiário:Elaine Minatel
Linha de fomento: Auxílio à Pesquisa - Regular
Processo FAPESP: 08/58491-1 - Mecanismos de proteção da distrofia muscular: estudo proteômico e terapia farmacológica
Beneficiário:Maria Julia Marques
Linha de fomento: Auxílio à Pesquisa - Regular
Processo FAPESP: 11/51697-6 - Mecanismos de acao do acido eicosapentanoico (epa) na protecao a mionecrose em fibras musculares distroficas
Beneficiário:Maria Julia Marques
Linha de fomento: Auxílio à Pesquisa - Regular